Lacrimal Gland Regeneration:Identification and Isolation of Progenitor Cells
Lacrimal Gland Regeneration:Identification and Isolation of Progenitor Cells
批准号:
7978066
负责人:
Darlene A Dartt
金额:
$26.6万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-01 至 2012-08-31
关键词:
AdultAgeAgingAmericanAntibodiesApoptosisAutoimmune DiseasesBromodeoxyuridineCell LineageCell ProliferationCellsDataDiseaseDuct (organ) structureElectrolytesEtiologyEye diseasesFilmFlow CytometryGlandGlial Fibrillary Acidic ProteinGoalsGrowth FactorHealthHumanImmunohistochemistryIn VitroIndividualInflammationInjection of therapeutic agentInjuryInterleukin-1LabelLaboratoriesLacrimal gland structureMenopauseMethodsMusMyoepithelialMyoepithelial cellNatural regenerationNecrosisNerveOperative Surgical ProceduresPainPopulationProliferatingProtein SecretionProteinsProtocols documentationRattusSalivary GlandsSjogren&aposs SyndromeStem cellsTissuesTransgenic MiceTransplantationTraumaUndifferentiatedWaterWestern BlottingWomanaqueouscell typeeye drynessimprovedin vivoinjuredirritationocular surfacepalliativeprogenitorpublic health relevancerepairedresearch studyrestorationtranscription factor
中文摘要
描述(由申请人提供):大约一千万美国人,主要是女性,患有干眼病,其由多种原因引起,包括衰老、屈光手术、绝经、自身免疫性疾病和创伤。虽然这些病症的病因各不相同,但所有病症的共同特征是泪腺分泌减少和眼表损伤,导致炎症、刺激和疼痛。目前的治疗方法只是治标不治本,因为它们针对的是眼表,而不是疾病的原因,泪腺分泌减少。大多数患有干眼病的个体可以从泪腺的蛋白质、电解质和水分泌的改善中受益。在干眼症中,泪腺细胞由于凋亡或坏死而减少,因此使用外源性祖细胞或刺激内源性再生来恢复患病泪腺将通过替换丢失的细胞来改善眼表面的健康,并且可以治愈干眼症。我们的实验室是第一个开发出一种可重复的方案,从成年大鼠眶外泪腺祖细胞,可用于修复患病的泪腺分离。这一发现表明,干细胞或能够再生的细胞存在于泪腺中,并且可以被激活以修复受损的组织。泪腺、腺泡、导管和肌上皮细胞的三种分化细胞类型的再生必须通过三种机制之一发生。新形成的分化细胞来源于相同细胞类型的细胞的增殖、来源于不同细胞类型的细胞的增殖或来源于未成熟的、未分化的祖细胞。该项目的总体目标是修复泪腺,恢复其分泌功能,并通过使用成人泪腺祖细胞开发治疗干眼症的新策略。在初步数据中,我们发现少量泪腺细胞的干细胞标志物呈阳性,可以重复分离。我们假设成人泪腺含有少量祖细胞,这些细胞可以在体外或体内诱导分化为功能性泪腺神经,腺泡,导管和肌上皮细胞,可以修复腺体。为了实现这些目标,我们将使用一组干细胞标记物进行免疫组织化学、蛋白质印迹和流式细胞术,以鉴定培养物中的祖细胞,并将这些标记物与其在体内泪腺中的定位进行比较。通过用对泪腺的主要细胞类型具有选择性的抗体进行双标记以确定祖细胞形成所需的细胞类型来确定祖细胞生态位。然后,我们将用溴脱氧尿苷标记来自受损小鼠泪腺的增殖细胞,以跟踪再生过程中的细胞谱系。我们还将使用GFAP和Ascl3转基因小鼠进行谱系追踪。使用一种类似于形成神经球的方案,我们将确定培养的泪腺祖细胞是否形成可用于修复的漂浮球。
公共卫生相关性:数百万美国人患有干眼病。原因是多种多样的,包括老化、屈光手术、绝经、自身免疫性疾病和导致眼表面损伤的创伤,从而导致疼痛、炎症和刺激。干眼没有治愈方法,并且由于泪腺是泪膜的水层的主要贡献者,因此使用干细胞替换患病的泪腺将改善眼表的健康。
英文摘要
DESCRIPTION (provided by applicant): About ten million Americans, predominantly women, suffer from dry eye disease, arising from a variety of causes including aging, refractive surgery, menopause, autoimmune disease, and trauma. Although the etiology of each of these conditions differs, a common feature of all is a decrease in lacrimal gland secretion and damage to the ocular surface resulting in inflammation, irritation, and pain. Current treatments are only palliative as they target the ocular surface, but not the cause of the disease, a decrease in lacrimal gland secretion. Most individuals with dry eye disease could benefit from improved protein, electrolyte, and water secretion from the lacrimal gland. In dry eye lacrimal gland cells are diminished by apoptosis or necrosis, thus restoration of diseased lacrimal gland using exogenous progenitor cells or stimulating endogenous regeneration would improve the health of the ocular surface by replacing lost cells and could cure dry eye. Our laboratory is the first to develop a reproducible protocol to isolate from adult, rat exorbital lacrimal gland progenitor cells that could be used to repair the diseased lacrimal gland. This finding suggests that stem cells or cells capable of regeneration are present in the lacrimal gland and can be activated to repair damaged tissue. The regeneration of the three differentiated cells types of the lacrimal gland, acinar, duct, and myoepithelial cells, must occur via one of three mechanisms. The newly formed differentiated cells are derived from proliferation of cells of the same cell type, derived from proliferation of cells of a different cell type or derived from immature, undifferentiated, progenitor cells. The overall goal of the project is to repair the lacrimal gland, restore its secretory function, and develop a new strategy to cure dry eye by using adult lacrimal gland progenitor cells. In preliminary data we found that a small number of lacrimal gland cells were positive for stem cell markers and could be reproducibly isolated. We hypothesize that the adult lacrimal gland contains a small population of progenitor cells and that these cells can be induced either in vitro or in vivo to differentiate into functioning lacrimal gland nerve, acinar, duct, and myoepithelial cells that can repair the gland. To achieve these goals, we will use a panel of stem cell markers for immunohistochemistry, western blotting, and flow cytometry to identify the progenitor cells in culture and compare these markers with their localization in the in vivo lacrimal gland. The progenitor cell niche will be determined by double labeling with antibodies selective for the major cell types of the lacrimal gland to determine which cell type is needed for progenitor cell formation. We will then label proliferating cells from injured mouse lacrimal glands with bromodeoxyuridine to follow cell lineages during regeneration. We will also use lineage tracing using GFAP and Ascl3 transgenic mice. Using a protocol similar to one that forms neurospheres, we will determine if lacrimal gland progenitor cells in culture form floating spheres that can be used for repair.
PUBLIC HEALTH RELEVANCE: Millions of Americans suffer from dry eye disease. The causes are varied and include aging, refractive surgery, menopause, autoimmune disease, and trauma causing damage to the ocular surface resulting in pain, inflammation, and irritation. There is no cure for dry eye and as the lacrimal gland is the primary contributor to the aqueous layer of the tear film, replacement of a diseased lacrimal gland using stem cells would improve the health of the ocular surface.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms underlying mustard gas-induced conjunctival injury and use of lipid mediators as medical countermeasures
-
批准号:10882060
-
项目类别:
-
资助金额:$58.33万
-
财政年份:2023
-
负责人:Darlene A Dartt
-
依托单位:
Construction of Conjunctival Equivalents Using Molecular Deposition Techniques
-
批准号:10338062
-
项目类别:
-
资助金额:$38.22万
-
财政年份:2020
-
负责人:Darlene A Dartt
-
依托单位:
Construction of Conjunctival Equivalents Using Molecular Deposition Techniques
-
批准号:10557095
-
项目类别:
-
资助金额:$39.4万
-
财政年份:2020
-
负责人:Darlene A Dartt
-
依托单位:
Construction of Conjunctival Equivalents Using Molecular Deposition Techniques
-
批准号:10089447
-
项目类别:
-
资助金额:$38.22万
-
财政年份:2020
-
负责人:Darlene A Dartt
-
依托单位:
Construction of Conjunctival Equivalents Using Molecular Deposition Techniques
-
批准号:9884619
-
项目类别:
-
资助金额:$39.4万
-
财政年份:2020
-
负责人:Darlene A Dartt
-
依托单位:
Conjunctival Goblet Cell Mucin Secretion in Inflammation and Its Resolution
-
批准号:9920424
-
项目类别:
-
资助金额:$5.97万
-
财政年份:2019
-
负责人:Darlene A Dartt
-
依托单位:
Conjunctival Goblet Cell NLRP3 Inflammasome in Ocular Surface Bacterial Infection
-
批准号:8461558
-
项目类别:
-
资助金额:$41.47万
-
财政年份:2012
-
负责人:Darlene A Dartt
-
依托单位:
Conjunctival Goblet Cell NLRP3 Inflammasome in Ocular Surface Bacterial Infection
-
批准号:8274619
-
项目类别:
-
资助金额:$43.65万
-
财政年份:2012
-
负责人:Darlene A Dartt
-
依托单位:
Conjunctival Goblet Cell NLRP3 Inflammasome in Ocular Surface Bacterial Infection
-
批准号:8663916
-
项目类别:
-
资助金额:$42.78万
-
财政年份:2012
-
负责人:Darlene A Dartt
-
依托单位:
Conjunctival Goblet Cell Mucin Secretion in Inflammation and Its Resolution
-
批准号:8990960
-
项目类别:
-
资助金额:$52.85万
-
财政年份:2009
-
负责人:Darlene A Dartt
-
依托单位:
Conjunctival Goblet Cell Mucin Secretion in Inflammation and Its Resolution
-
批准号:9195092
-
项目类别:
-
资助金额:$52.82万
-
财政年份:2009
-
负责人:Darlene A Dartt
-
依托单位:
Conjunctival Goblet Cell Mucin Secretion in Inflammation and Its Resolution
-
批准号:8065897
-
项目类别:
-
资助金额:$45.88万
-
财政年份:2009
-
负责人:Darlene A Dartt
-
依托单位:
Conjunctival Goblet Cell Mucin Secretion in Inflammation and Its Resolution
-
批准号:10311475
-
项目类别:
-
资助金额:$54.08万
-
财政年份:2009
-
负责人:Darlene A Dartt
-
依托单位:
Conjunctival Goblet Cell Mucin Secretion in Inflammation and Its Resolution
-
批准号:7810577
-
项目类别:
-
资助金额:$48.02万
-
财政年份:2009
-
负责人:Darlene A Dartt
-
依托单位:
Conjunctival Goblet Cell Mucin Secretion in Inflammation and Its Resolution
-
批准号:9402607
-
项目类别:
-
资助金额:$52.78万
-
财政年份:2009
-
负责人:Darlene A Dartt
-
依托单位:
Conjunctival Goblet Cell Mucin Secretion in Inflammation and Its Resolution
-
批准号:8268449
-
项目类别:
-
资助金额:$45.85万
-
财政年份:2009
-
负责人:Darlene A Dartt
-
依托单位:
Conjunctival Goblet Cell Mucin Secretion in Inflammation and Its Resolution
-
批准号:8637283
-
项目类别:
-
资助金额:$54.21万
-
财政年份:2009
-
负责人:Darlene A Dartt
-
依托单位:
Conjunctival Goblet Cell Mucin Secretion in Inflammation and Its Resolution
-
批准号:8788355
-
项目类别:
-
资助金额:$49.98万
-
财政年份:2009
-
负责人:Darlene A Dartt
-
依托单位:
Conjunctival Goblet Cell Mucin Secretion in Inflammation and Its Resolution
-
批准号:10540321
-
项目类别:
-
资助金额:$55.75万
-
财政年份:2009
-
负责人:Darlene A Dartt
-
依托单位:
Conjunctival Goblet Cell Mucin Secretion in Inflammation and Its Resolution
-
批准号:7632629
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:Darlene A Dartt
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
-
批准号:82505677
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:吕雨霏
-
依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
-
批准号:82574874
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:刘天华
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位: